Jason Laufer, Chief Executive Officer
Jason is a seasoned veteran in the biopharmaceutical field, with early experience in clinical and regulatory affairs at Pfizer (PFE), and at a senior level, as Managing Director of CELLGRO®/Mediatech; acquired by Corning (GLW). Mr. Laufer, operating via the VIDA Group, has provided management consulting services to a range of European, US, and Israeli Pharma companies, and was appointed CEO of ELUTEX, a developer of drug-eluting stents. Prior to assuming the helm at RDD, Mr. Laufer managed Global Business Development and Licensing for URL Pharma, a specialty pharma company with a portfolio in gout (Colcrys), lipid regulation (Fibricor), antibiotics (Bactrim), malaria (Qualaquin) as well as a generic drug portfolio of 250 ANDAs. URL Pharma was acquired by Takeda Pharmaceuticals in 2012 for $800 million plus potential follow-on payments.
Nir Barak M.D., Chief Medical Officer and Founder
Dr. Barak’s career has focused on the integration of clinical medicine, basic research, and pharmaceutical development. He served as an attending physician in the department of internal medicine at Beilinson Hospital for 10 years.
Dr. Barak began engaging in drug development driven by feedback received from patients regarding shortcomings in available treatment options. Nir served as CSO and Founder of Obecure Ltd. — a company focused on re-purposing Betahistine as an anti-obesity agent. In 2008 after learning from patients of the dearth of treatment options for ano-rectal diseases, he founded RDD Pharma. Under Nir’s leadership, RDD has attracted significant investment from OrbiMed Advisors. — a multinational private equity fund.
Dr. Barak earned his MD from the Sackler School of Medicine, Tel-Aviv University, and is Board Certified in Internal Medicine and Clinical Nutrition.
Al Medwar M.B.A., Executive Vice President — Global Relations
Al brings nearly 30 years of pharmaceutical experience to RDD, much of which has been with development stage companies in a number of roles including sales, marketing, business development and investor/public relations. Prior to joining the company, Mr. Medwar was Senior Vice President, Corporate and Business Development for BioDelivery Services, where he spent eleven years and played an important role in building the company from a development to a commercial stage entity. Al was also responsible for securing and overseeing a number of partnerships for the company's products and also interacted closely with the investor community. In addition, Mr. Medwar was the Head of Oncology Marketing at EMD Pharmaceuticals, the U.S. subsidiary of Merck KGaA, where he was responsible for dveloping the global market for a pipeline of oncology products. Mr. Medwar was also the Marketing Director for Triangle Pharmaceuticals, a start-up company focusing on the development and commercialization of compounds for HIV and hepatitis. Mr. Medwar's pharmaceutical career began in sales at Glaxo Wellcome. After six years of sales experience, he held positions of increasing marketing responsiblilty for a number of products including Wellbutrin SR and Zofran. Mr. Medwar received a Bachelor of Science degree from Cornell University and a Masters of Business Administration from Bentley University.
Howard Rice, RPh, BPharm, Vice President — Pharmaceuticals
Howard brings 30+ years of pharmaceutical formulation and development experience to RDD. Mr. Rice serves as a Director at Tilary Ltd, the Israel agent for American Biotech Labs (USA) and is the Israel delegate to the Federation International Pharmaceutique (FIP) – an NGO within the World Health Organization (WHO). He served as Vice President of the FIP for 8 years, and he is the former Chairman of the Pharmaceutical Association of Israel.
Mr. Rice earned a B.Pharm from the School of Pharmacy, University of London.
Robert Niecestro, Ph.D. — Regulatory Advisor
Robert is the managing director of Accelapharm. He serves as the Head of Regulatory Affairs and Vice President of Axsome Therapeutics. Dr. Niecestro also serves as the Executive Vice President of Clinical & Regulatory at TG Therapeutics, Inc. He was a regulatory consultant to Stemline Therapeutics from 2006 until December 2012. Dr. Niecestro served as the VP Clinical & Regulatory Affairs at Keryx Biopharmaceuticals, Inc., where he negotiated six SPA agreements and filed the NDA for ferric citrate. He has held executive and senior management roles at Andrx Laboratories, Eisai Inc. and Organon Inc. He has been involved in the filing of over 45 Investigational New Drug (IND) applications. He has over 60 peer-reviewed publications and holds three patents.
Robert Shleypak, CCRN, BSN — Director, Clinical Operations
Robert has been monitoring multinational Phase I, II, and III clinical studies since 2005. Prior to joining RDD Pharma, he devoted nine years to Quintiles International as a Clinical Research Specialist and Clinical Lead working on six multinational trials. At Quintiles, Robert had comprehensive responsibility for planning patient recruitment, retention and clinical monitoring during the course of the studies. Prior to Quintiles, Robert was a Clinical Research Monitor at Rafa Laboratories.
Our team is balanced by responsible stewardship and innovative drive.
• OrbiMed Advisors
• Ofakim Hi-Tech Ventures
• Capital Point Ltd.
• Agate Medical